CVE-2026-1025: IBM Common Licensing · Cross-site Scripting
Affects IBM Common LicensingSource CVE Database V5
Not known to be exploited · CVSS 6.1 Medium.
Data as of 1 Nov 2026, 22:58 UTC
- EPSS
- 0.2% chance of exploitation in 30 days – higher than 16% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:NExploitation evidence
Disclosed: evidence found.
CVE published 18 Sep 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 1 Nov 2026.
What to do
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| IBMCommon Licensing | Affected
| Fixed in– |
CPE configurations (2)
cpe:2.3:a:ibm:common_licensing:agent:*:*:*:*:*:*:*cpe:2.3:a:ibm:common_licensing:art:*:*:*:*:*:*:*
AI-suggested
Until a fix is available, users should exercise caution with untrusted input in the web UI and consider applying any recommended workarounds from IBM.
Description
IBM Common Licensing versions including Agent 9.0, 9.0.0.1, 9.0.0.2 and ART 9.0, 9.0.0.1, 9.0.0.2 contain a cross-site scripting (XSS) vulnerability. This flaw allows users to inject arbitrary JavaScript into the web interface, potentially altering functionality and leading to credential disclosure within a trusted session. The vulnerability is rated medium severity with a CVSS score of 6.1.